Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice
- PMID: 16497559
- DOI: 10.1016/j.ymthe.2005.12.011
Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice
Abstract
Among numerous gene therapeutic strategies for cancer treatment, gene transfer by conditionally replicative adenovirus (CRAd) of interferon-gamma (IFN-gamma) may be useful because of the possibility that it will yield IFN-gamma-mediated antiangiogenesis, immune responses, and CRAd-mediated oncolysis. In this study, we constructed a human TERT promoter-mediated oncolytic adenovirus targeting telomerase-positive cancers and armed with a mouse or human IFN-gamma gene to generate novel immune gene-viral therapeutic systems, CNHK300-mIFN-gamma and CNHK300-hIFN-gamma, respectively. The systems can specifically target, replicate in, and lyse cancer cells, while sparing normal cells. The advantage of these systems is that the number of transgene copies and their expression increase markedly via viral replication within infected cancer cells, and replicated viral progeny can then infect additional cancer cells within the tumor mass. CNHK300-mIFN-gamma induced regression of xenografts in liver cancer models in both immunodeficient and immunocompetent mice by triplex mechanisms including selective oncolysis, antiangiogenesis, and immune responses. We conclude that combining immune gene therapy and oncolytic virotherapy can enhance antitumor efficacy as a result of synergism between CRAd oncolysis and transgene composite antitumor responses.
Similar articles
-
[Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].Zhonghua Yi Xue Za Zhi. 2004 Jun 2;84(11):943-8. Zhonghua Yi Xue Za Zhi. 2004. PMID: 15329284 Chinese.
-
Telomerase-dependent oncolytic adenovirus for cancer treatment.Gene Ther. 2003 Aug;10(15):1241-7. doi: 10.1038/sj.gt.3301987. Gene Ther. 2003. PMID: 12858189
-
Potent antitumoral effects of a novel gene-viral therapeutic system CNHK300-mEndostatin in hepatocellular carcinoma.Chin Med J (Engl). 2005 Feb 5;118(3):179-85. Chin Med J (Engl). 2005. PMID: 15740644
-
Targeting gene-virotherapy of cancer.Cell Res. 2006 Jan;16(1):25-30. doi: 10.1038/sj.cr.7310005. Cell Res. 2006. Retraction in: Cell Res. 2006 Aug;16(8):740. doi: 10.1038/sj.cr.7310088. PMID: 16467873 Retracted. Review.
-
Replication-selective oncolytic viruses in the treatment of cancer.Cancer Gene Ther. 2005 Feb;12(2):141-61. doi: 10.1038/sj.cgt.7700771. Cancer Gene Ther. 2005. PMID: 15472714 Review.
Cited by
-
Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes.Adv Cancer Res. 2012;115:1-38. doi: 10.1016/B978-0-12-398342-8.00001-X. Adv Cancer Res. 2012. PMID: 23021240 Free PMC article. Review.
-
Oncolytic viruses in cancer therapy.Cancer Lett. 2007 Sep 8;254(2):178-216. doi: 10.1016/j.canlet.2007.02.002. Epub 2007 Mar 23. Cancer Lett. 2007. PMID: 17383089 Free PMC article. Review.
-
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.Signal Transduct Target Ther. 2022 Apr 6;7(1):117. doi: 10.1038/s41392-022-00951-x. Signal Transduct Target Ther. 2022. PMID: 35387984 Free PMC article. Review.
-
Adenovirus-mediated decorin expression induces cancer cell death through activation of p53 and mitochondrial apoptosis.Oncotarget. 2017 Sep 8;8(44):76666-76685. doi: 10.18632/oncotarget.20800. eCollection 2017 Sep 29. Oncotarget. 2017. PMID: 29100340 Free PMC article.
-
Conditionally replicating adenoviruses for cancer treatment.Curr Cancer Drug Targets. 2007 May;7(3):285-301. doi: 10.2174/156800907780618301. Curr Cancer Drug Targets. 2007. PMID: 17504125 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical